Latham-Led Triumvira Immunologics Clinches $100M Series A
Triumvira Immunologics, which makes T cell therapies for patients with tumors, said Thursday it raised $100 million in a Series A funding round, guided by Latham & Watkins LLP, to support...To view the full article, register now.
Already a subscriber? Click here to view full article